eShowcase: CogState DataPoint
Web-based system puts sponsors running brain function clinical trials in the know
Web-based system puts sponsors running brain function clinical trials in the know
CogState Ltd. (Melbourne, Australia) has released the first real-time cognitive data monitoring system, called DataPoint, which allows pharmaceutical companies to access, monitor, and review data from global, multicenter trials at a central and secure Web-based location. The tool is targeted toward trials where cognitive function is the primary endpoint and represents a significant technological departure from paper and pencil cognitive brain function measurements.
One of the main benefits, says CogState, is that DataPoint enables clinical researchers to respond much more quickly to data coming out of clinical trials. For example, DataPoint delivers cleaned datasets and cognitive reports to pharmaceutical clients within hours of study completion, compared to the usual weeks. DataPoint also functions as the main point of contact between sponsors and CogState, and all study-specific software and manuals required to upload data and run a trial are accessible from one central source.
CogState Ltd., +61-3-9664-1300, www.cogstate.com
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.
